Reactions to the pertussis component of the original commercial batches of quadruple vaccine against poliomyelitis, diphtheria, tetanus and pertussis (Quadrilin, Glaxo Laboratories) gave some cause for concern. Severe reactions were found to be more common in infants under 6 months of age than in older infants.A modified quadruple vaccine, which has been used in N. Ireland since October 1964, was found to give rise to significantly fewer and milder reactions. This vaccine when given in three doses separated by intervals of 6–9 weeks and 6 months to fifty-eight infants most of whom were 6–7 months of age at the start of immunization was found to give a satisfactory immunological response.

1966-03-01·Journal of Hygiene

A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine

Article

作者: A. J. H. Tomlinson ; J. L. Henry ; Joan R. Davies ; Joan M. Barnes ; E. S. Jaikaran ; P. J. Mason ; A. J. Beale

Quadruple vaccine containing 75 D antigen units of killed type 1 poliovirus was given to children at ages 2, 3 and 4 months followed by a booster dose at 15 months.The serological response to the primary course was difficult to assess owing to maternal antibody. Antibody titres to the type 1 component after the booster dose were very satisfactory and about 10 times higher than those observed in a similar group of children given attenuated vaccine. Response to the poliovirus types 2 and 3 in the quadruple vaccine was less satisfactory.Graded doses of attenuated poliovirus type 1 were fed to the children 2 months after the primary course and 1 month after the booster dose. Children who had received no poliovaccine and children immunized with attenuated vaccine were included for comparison.Immunization with killed vaccine did not greatly affect the size of the minimal infecting dose of live virus but reduced both the duration of the subsequent infection and the titre of virus in the faeces.The epidemiological significance of these findings is discussed.

100 项与 DTP-hepatitis-B vaccine (Ecovac) (Panacea Biotec) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
白喉	印度	Panacea Biotec Ltd.	2008-01-25
乙型肝炎	印度	Panacea Biotec Ltd.	2007-12-21
破伤风	印度	Panacea Biotec Ltd.	2007-12-19
百日咳	印度	Panacea Biotec Ltd.	2007-12-16